Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TAK-491 in Subjects With Essential Hypertension.

Trial Profile

A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of TAK-491 in Subjects With Essential Hypertension.

Completed
Phase of Trial: Phase III

Latest Information Update: 04 Aug 2018

At a glance

  • Drugs Azilsartan medoxomil (Primary) ; Olmesartan medoxomil
  • Indications Essential hypertension
  • Focus Registrational; Therapeutic Use
  • Sponsors Takeda Global Research and Development Center
  • Most Recent Events

    • 04 Aug 2018 Results of two post hoc analyses (first pooled analysis: n= 1610; NCT00696241 and NCT00696436; second analysis: n=1020; NCT01033071) comparing effectiveness of azilsartan medoxomil (AZL-M) and the fixed-dose combination of AZL-M with chlorthalidone (AZL-M/CLD) versus the ARB olmesartan (OLM) and the OLM fixed-dose combination with hydrochlorothiazide (OLM/HCTZ) in blacks versus white patients with systemic hypertension, published in the American Journal of Cardiology.
    • 21 Jun 2010 Results presented at the 20th European Meeting on Hypertension.
    • 03 May 2010 Results were presented at the American Society of Hypertension, Inc. 25th Annual Scientific Meeting, according to a Takeda Global Research and Development Center media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top